Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Francesca Bruce

Francesca Bruce has been writing news and analysis about all things affecting the pharmaceutical industry since 2008. She has paid special attention to policy and regulatory developments but particularly likes to write about market access and how medicines may  - or may not  -  make it to patients. She generally writes about Europe, but really enjoys uncovering news from further corners of the globe, especially Latin America and the Middle East.

Writes for:

Latest From Francesca Bruce

German Insurers Want End To Free Pricing In Amnog Review

Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.

Europe Germany

Investors Spooked By High Prices For Advanced Therapies

To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.

Cost Effectiveness Business Strategies

Cost Offsets Crucial For Uptake Of Advanced Therapies

To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.

Market Access Policy

Australian Funding Commitment For New Medicines Wins Industry Thumbs Up

The pharma and biotech industries have welcomed Australia’s coronavirus recovery budget, which also sets aside funding for research into COVID-19 vaccines and makes positive changes to R&D tax incentives.

Australia Market Access

How To Mitigate Evidence Gaps For Advanced Therapies

Existing evidence supporting advanced therapies through health technology assessments may be flawed, but economic modeling approaches could help solve some of the problems.

Europe Clinical Trials

Middle East And North Africa Dip Toes In HTA And Access Agreements

Saudi Arabia is set to introduce a new pricing policy that will affect the rest of the region.

Middle East and Africa Algeria
See All
UsernamePublicRestriction

Register